Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

Item

http://www.wikidata.org/entity/Q53544370

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@en

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@nl

type

Item

label

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@en

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@nl

prefLabel

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@en

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

@nl

P1476

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease

@en

P2093

A Buisson

http://www.w3.org/2001/XMLSchema#string

A-L Boucher

http://www.w3.org/2001/XMLSchema#string

B Pereira

http://www.w3.org/2001/XMLSchema#string

F Goutorbe

http://www.w3.org/2001/XMLSchema#string

G Bommelaer

http://www.w3.org/2001/XMLSchema#string

M Goutte

http://www.w3.org/2001/XMLSchema#string

P2860

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

P304

1113-1119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ECCO-JCC/JJV150

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

R Minet-Quinard

P577

2015-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26351383

http://www.w3.org/2001/XMLSchema#string

P921

Aka